Codexis Reports First Quarter 2023 Financial Results
We use our propietary CodeEvolver® technology platform to engineer enzymes that are highly stable to the harsh conditions of the gastrointestinal (GI) tract, including the low pH of the stomach and the protease-rich upper intestines. Our engineered enzymes are active within the GI tract, where they degrade substrates that originate from diet or enteric recycling. Highly stable and active recombinant oral enzyme replacement therapies potentially can provide many benefits to patients, including reducing dosing burden as compared to animal-derived products, easing dietary restrictions, and improving quality of life.
Program | Indication | IND-enabling studies | Phase 1 | Phase 2 | Phase 3 | Partner |
---|---|---|---|---|---|---|
CDX-7108 | Exocrine pancreatic insufficiency |
IND-enabling studies Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
![]() |
CDX-6114 | Phenylketonuria |
IND-enabling studies Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
![]() |
1 Co-development by Nestlé Health Science and Codexis
2 Nestlé Health Science licensed CDX-6114 for world-wide development